Ginsenoside Rb1 Suppresses AOM/DSS-induced Colon Carcinogenesis

Area of Science:

• Oncology
• Pharmacology
• Microbiology

Background:

• Colorectal cancer (CRC) is a leading global cancer with limited treatment options due to side effects and resistance.
• Current CRC therapies like surgery, radiotherapy, and chemotherapy have significant drawbacks.

Purpose of the Study:

• To investigate the anti-cancer effects of Ginsenoside Rb1, a key component of ginseng.
• To evaluate Ginsenoside Rb1's potential in preventing and treating inflammation-associated colorectal cancer.

Main Methods:

• An inflammation-based colorectal cancer model was established using Azoxymethane (AOM) and Dextran sodium sulfate (DSS) in mice.
• The study observed the effects of Ginsenoside Rb1 on this model and analyzed changes in gut microbiota composition.

Main Results:

• Ginsenoside Rb1 significantly reduced pro-inflammatory cytokines (TNF-α, IL-6, IL-17A, IL-33, IL-1β, IL-22) and increased anti-inflammatory cytokine (IL-10).
• Significant alterations in gut microbiota composition were observed following Ginsenoside Rb1 treatment.
• Ginsenoside Rb1 demonstrated a significant protective effect against AOM/DSS-induced colon carcinogenesis.

Conclusions:

• Ginsenoside Rb1 can prevent inflammation-associated colorectal cancer development.
• This compound may offer an effective therapeutic strategy for CRC by mitigating chronic inflammation and restoring the gut microenvironment.